Methods and systems for measuring progesterone metabolites

Tandem mass spectrometry methods and systems provide accurate quantification of progesterone metabolites, addressing the challenge of distinguishing pathological from normal physiological changes, thereby enhancing the early diagnosis of pregnancy complications.

JP2024542948AInactive Publication Date: 2024-11-19LABORATORY CORPORATION OF AMERICA HOLDINGS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523428
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-27
Filing Date
2022-10-27
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods lack the ability to accurately distinguish between pathological and normal physiological changes in progesterone metabolites, particularly in conditions like intrahepatic cholestasis of pregnancy, which is crucial for early diagnosis and targeted obstetric care.

Method used

The use of tandem mass spectrometry (MS/MS) to generate and detect precursor and product ions from progesterone metabolites, such as progesterone sulfate, allowing for precise quantification through methods and systems that include sample preparation, chromatographic separation, and mass spectrometry analysis.

Benefits of technology

Enables sensitive and specific detection of progesterone metabolites, facilitating early diagnosis of pregnancy complications and guiding therapeutic interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542948000010
    Figure 2024542948000010
  • Figure 2024542948000011
    Figure 2024542948000011
  • Figure 2024542948000012
    Figure 2024542948000012
Patent Text Reader

Abstract

Methods and systems are disclosed that use liquid chromatography-tandem mass spectrometry (LC-MS / MS) for the detection and / or analysis of progesterone metabolites, such as progesterone sulfate, in biological samples. In some cases, the amount of progesterone sulfate may be used to distinguish whether cutaneous pruritus of pregnancy is an early sign of (ICP) or is due to benign pruritus of pregnancy. The system may optionally include a station for partial purification of progesterone metabolites from other components in the sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Field The inventive subject matter disclosed herein relates to methods and systems for analyzing progesterone metabolite biomarkers. In certain embodiments, measurement of the biomarkers may be used for clinical diagnosis. [Background technology]

[0002] background Biomarkers such as hormones, vitamins, and metabolites can be used for screening or diagnosis of certain disorders. For example, various metabolites of progesterone can be important indicators of various physiological conditions such as menopause and breast cancer. In addition, progesterone metabolites can play a role in ovulation and the ability to maintain a healthy pregnancy. Thus, a challenge in obstetrics is to distinguish pathological signs from signs related to normal changes in cognition. Progesterone metabolites (including certain progesterone sulfates) can be good indicators of the effectiveness of various therapeutic compounds to reduce pregnancy complications such as intrahepatic cholestasis of pregnancy (ICP) and complications that may result from the aforementioned complications (such as fetal death, preterm birth, and / or iatrogenic preterm birth). For example, in some cases, it is important to distinguish whether cutaneous pruritus of pregnancy is an early sign of ICP or is due to benign pruritus of pregnancy (Hayyeh et al., Hepatology 63:1287-1298 (2016)). ICP is characterized by elevated serum bile acids and is complicated by spontaneous preterm labor and stillbirth. Biomarkers for ICP would be crucial for early diagnosis and treatment, and would be able to distinguish it from other maternal diseases. Measurement of progesterone sulfate would allow obstetric care to be targeted to high-risk populations. There is therefore a need to develop analytical techniques that can be used for the measurement of progesterone metabolites. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Hayyeh et al.,Hepatology 63:1287-1298(2016) Summary of the Invention

[0004] Abstract In some embodiments, a method for determining the presence or amount of a metabolite of progesterone in a sample by mass spectrometry is disclosed. In one embodiment, tandem mass spectrometry (MS / MS) is used. The method may include (a) generating one or more precursor ions from a progesterone metabolite; (b) generating one or more product ions of said one or more precursor ions; and (c) detecting the presence or amount of one or more precursor ions generated in step (a) or one or more product ions of step (b), or both. In one embodiment, the detected ions are used to determine the amount of a progesterone metabolite in the sample. In certain embodiments, the progesterone metabolite is progesterone sulfate. In certain embodiments, the mass spectrometry is tandem mass spectrometry.

[0005] Also disclosed is a system for carrying out any of the methods or steps of the methods disclosed herein.In certain embodiments, the system may include a station and / or component for providing a sample; a station and / or component for partially purifying the progesterone metabolites in the sample from other components, if necessary; a station and / or component for chromatographically separating the progesterone metabolites in the sample from other components, if necessary; a station and / or component for mass spectrometry to generate one or more precursor ions and one or more product ions from the progesterone metabolites; and a station and / or component for analyzing mass spectrum to determine the presence or amount of the progesterone metabolites in the test sample.In some embodiments, certain stations or components are combined as a single station and / or component.In certain embodiments, the progesterone metabolite is progesterone sulfate.In certain embodiments, at least one of the stations may be controlled by a computer.

[0006] Also disclosed is a computer program product tangibly embodied in a non-transitory machine-readable storage medium that includes instructions configured to cause the disclosed system or any portion (e.g., component) of the disclosed system to operate and / or perform one or more steps of any of the disclosed methods.

[0007] BRIEF DESCRIPTION OF THE DRAWINGS The present disclosure may be better understood with reference to the following non-limiting drawings. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 shows a flow chart of a method for quantitative analysis of progesterone metabolites according to one embodiment of the present disclosure.

[0009] [Diagram 2]FIG. 2 illustrates a system for quantitative analysis of progesterone metabolites according to one embodiment of the present disclosure.

[0010] [Diagram 3] FIG. 3 illustrates an exemplary computing device according to various embodiments of the present disclosure.

[0011] [Figure 4] FIG. 4 shows PM3S multiple reaction monitoring (MRM) chromatograms (10 pairs) showing analyte peaks at the 399.400→97.100 transition using Turbo Spray LC-MS / MS according to certain embodiments of the present disclosure.

[0012] [Diagram 5] FIG. 5 shows MRM chromatograms of PM4S and PM5S showing the analyte peak at the 397.3→97.0 transition for PM5S and the 397.2→97.0 transition for PM4S in accordance with certain embodiments of the present disclosure.

[0013] [Figure 6] FIG. 6 shows MRM chromatograms of PM2DiS and PM3DiS showing the sum of the analyte peaks of the 479.098→381.2+479.099→381.2+479.100→381.2+479.101→381.2+479.102→381.2 transitions for PM2DiS and the sum of the 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.1 transitions for PM3DiS in accordance with certain embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description The disclosed subject matter will now be more fully described after reference to the following accompanying description and drawings, which illustrate some, but not all, of the disclosed subject matter. The disclosed subject matter may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Like numbers refer to like elements throughout.

[0015] Those skilled in the art to which the disclosed subject matter pertains will devise numerous modifications and other embodiments of the disclosed subject matter described herein having the benefit of the teachings present in the description and the associated drawings. It is therefore to be understood that the disclosed subject matter is not limited to the specific embodiments disclosed herein, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms have been used herein, these terms are used in a generic and descriptive sense only and are not intended to be limiting of the invention. Furthermore, any reference referred to as "incorporated herein" should be understood to be incorporated in its entirety. Definitions and Explanations

[0016] Although the following terms are believed to be well understood by those skilled in the art, definitions are provided below to facilitate the description of the subject matter disclosed herein. Other definitions can be found throughout the specification. Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the subject matter described herein belongs.

[0017] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the present disclosure are approximations, the numerical values ​​set forth in the specific examples are reported to the degree of precision possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Moreover, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed within that range. For example, recitation of a range of 1 to 10 should be considered to include any and all subranges between the minimum value of 1 and the maximum value of 10 (and both ends inclusive); i.e., all subranges beginning with a minimum value of 1 or more (e.g., 1 to 6.1) and ending with a maximum value of 10 or less (e.g., 5.5 to 10).

[0018] The terms "a," "an," and "the" as used in this application, including the claims, refer to "one or more." Thus, for example, a reference to "a cell" includes a plurality of such cells, unless the context clearly indicates to the contrary (e.g., a plurality of cells).

[0019] As used herein, "AMR" or "analytical measurement range" is the range of analyte values ​​that can be measured directly in a sample by a method without any dilution, concentration, or other pretreatment that is not part of the useful assay process.

[0020] As used herein, the term "analytical column" refers to a chromatography column having a chromatographic plate sufficient to separate the components of a test sample matrix. Preferably, the components eluted from the analytical column are separated in a manner that allows the presence or amount of the analyte(s) of interest to be determined. In some embodiments, the analytical column comprises particles with an average particle size of about 5 μm or less. In some embodiments, the analytical column is a functionalized silica or polymer-silica hybrid, or a polymer particle or monolithic silica stationary phase (such as a phenyl-hexyl functionalized analytical column). Analytical columns can be distinguished from "extraction columns," which are typically used to separate or extract retained materials from non-retained materials to obtain a "purified" sample for further purification or analysis.

[0021] As used herein, an "analyte" is a constituent element that can be designated a measurable quantity.

[0022] As used herein, "analytical interference" refers to an artificial increase or decrease in the apparent concentration, activity, or intensity of an analyte due to the presence of a substance that reacts specifically or nonspecifically with either the detection reagent or the signal itself.

[0023] As used herein, the term "atmospheric pressure chemical ionization" or "APCI" refers to a mass spectrometry method that produces ions by ion-molecule reactions occurring in a plasma at atmospheric pressure. The plasma is sustained by an electric discharge between the spray capillary and a counter electrode. The ions are then typically drawn into a mass analyzer by using a series of differentially pumped skimmer stages. Heated and counterflow of preheated N2 gas may be used to improve solvent removal. Gas-phase ionization in APCI may be more effective than ESI for the analysis of less polar species.

[0024] The term "atmospheric pressure photoionization" or "APPI" as used herein refers to a form of mass spectrometry in which the photoionization mechanism of molecule M is photon absorption and electron ejection to form molecule M+. Because the photon energy is typically just above the ionization potential, the molecular ion is not susceptible to dissociation. In many cases, it may be possible to analyze samples without the need for chromatography, thus saving significant time and money. In the presence of water vapor or protic solvents, the molecular ion can abstract H to form MH+. This formation tends to occur when the proton affinity of M is high. This formation does not affect quantitative accuracy since the sum of M+ and MH+ is constant. Compounds in protic solvents are usually observed as MH+, whereas non-polar compounds usually form M+ (see, e.g., Robb et al., Anal. Chem. 72(15):3653-3659 (2000)).

[0025] As used herein, the term "biological sample" refers to a sample obtained from a biological source, including, but not limited to, animals, cell cultures, organ cultures, etc. Suitable samples include cell-free DNA, blood, plasma, serum, urine, saliva, tears, nasopharyngeal swabs, cerebrospinal fluid, organs, hair, muscle, or other tissue samples.

[0026] As used herein, the term "chemical ionization" refers to a method in which a reagent gas (eg, ammonia) is subjected to electron bombardment and ions of the analyte are formed by interaction of the reagent gas ions with the analyte molecules.

[0027] As used herein, "chromatography" refers to a process by which a mixture of chemicals carried by a liquid or gas is separated into components as a result of differences in the distribution of the chemicals as they flow around or over a liquid or solid stationary phase.

[0028] The term "electron ionization" as used herein refers to the method by which an analyte of interest in the gas or vapor phase interacts with an electron stream. Impact of the electrons with the analyte produces analyte ions, which can then be subjected to mass spectrometry techniques.

[0029] As used herein, the term "electrospray ionization" or "ESI" refers to a method in which a solution is passed along a short length of capillary tube and a high potential, either positive or negative, is applied to the end of the tube. Upon reaching the end of the tube, the solution may be vaporized (atomized) into a jet or spray of very small droplets in solvent vapor. This mist of droplets may flow through a slightly heated evaporation chamber to prevent condensation and to evaporate the solvent. As the droplets get smaller, the surface charge density increases until natural repulsion between like charges releases ions and neutral molecules.

[0030] As used herein, the term "field desorption" refers to a method in which a non-volatile test sample is placed on an ionizing surface and a strong electric field is used to generate analyte ions.

[0031] As used herein, the term "HPLC" or "high performance liquid chromatography" refers to liquid chromatography that increases the degree of separation by forcing a mobile phase under pressure through a stationary phase (typically a densely packed column). Chromatographic columns typically include a support (i.e., packing) to facilitate separation (i.e., fractionation) of chemical moieties. The support may include microparticles. The particles include binding surfaces that interact with various chemical moieties to facilitate separation of chemical moieties, such as the biomarker analytes quantified in the experiments described herein. One suitable binding surface is a hydrophobic binding surface, such as an alkyl binding surface. The alkyl binding surface may include C-4, C-8, or C-18 linked alkyl groups, preferably C-18 linked groups. Chromatographic columns include an inlet for receiving a sample and an outlet for discharging an effluent containing the fractionated sample. In this method, a sample (or a pre-purified sample) may be applied to the inlet of the column, eluted with a solvent or solvent mixture, and discharged from the outlet. Different solvent modes may be selected to elute different analytes of interest. For example, liquid chromatography may be performed using gradient mode, isocratic mode, or polymorphic (ie, mixed) mode.

[0032] As used herein, the terms "ionization" and "ionizing" refer to the process of producing analyte ions having a net charge equivalent to one or more electrons. Anions are ions with a negative net charge of one or more electrons, while cations are ions with a positive net charge of one or more electrons.

[0033] As used herein, the term "ion summation" or "signal summation" refers to a technique of summing individual chromatograms (e.g., tandem mass spectrometry) of essentially identical transitions in a manner that increases the signal-to-noise ratio. By programming multiple transitions in the same cycle time, the dwell time for each transition is reduced, and it is possible to sum the signals even though the intensity of the signal for each transition is almost the same. Since the noise is random, summing the repetitions of the signal will increase the signal approximately linearly, while the random noise will decrease (see, for example, Pauwels et al., Anal. Bioanal. Chem., 407:6191-6199 (2015)).

[0034] As used herein, "interference" refers to the negative impact of the presence of non-analytes in a sample due to, for example, hemolysis, lipemia, and / or jaundice, on being able to accurately measure an analyte.

[0035] As used herein, "liquid chromatography" or "LC" refers to a process in which one or more components of a fluid are selectively retarded as the fluid permeates uniformly through a column or capillary passage of finely divided material. As the bulk fluid moves relative to the stationary phase(s), the retardation is due to partitioning of the components of the mixture between one or more stationary phases and the bulk fluid (i.e., the mobile phase). Liquid chromatography includes reversed-phase liquid chromatography (RPLC), high-performance liquid chromatography (HPLC), and high-turbulence liquid chromatography (HTLC).

[0036] As used herein, "LOD" or "limit of detection" is the lowest amount of analyte in a sample that can be detected with a stated probability. Typically, LOD is expressed as the upper limit of blank (LOB) + 1.645 x SD (or 2 x SD) of the low measured value of the sample. Also, as used herein, "LLOQ" or "lower limit of quantification" is the lowest amount of analyte in a sample that can be quantified with a stated acceptable precision and accuracy.

[0037] As used herein, the term "matrix-assisted laser desorption ionization" or "MALDI" refers to a method in which a non-volatile sample is subjected to laser irradiation, thereby desorbing and ionizing analytes in the sample by various ionization pathways, including photoionization, protonation, deprotonation, and cluster decay. In the case of MALDI, the sample is mixed with an energy absorbing matrix to facilitate desorption of the analyte molecules.

[0038] The term "mass spectrometry" or "MS" as used herein generally refers to a method of filtering, detecting, and measuring ions based on the mass-to-charge ratio, or "m / z," of the ions. In MS techniques, one or more molecules of interest are ionized and then the ions are introduced into a mass spectrometer where a combination of electric fields causes the ions to travel through space in a path that is mass ("m") and charge ("z") dependent. The term "tandem mass spectrometry" or "MS / MS" refers to a type of mass spectrometry in which molecules are ionized in a first step to form parent (or precursor) ions, which are then separated by their mass-to-charge (m / z) ratio. Parent ions of a particular m / z are then selected and fragmented to form daughter (or product or fragment) ions, which are then separated by their m / z ratio. A triple quadrupole mass spectrometer uses the first and third quadrupoles as a mass filter and the second quadrupole for fragmentation, for example by collision-induced desorption, ionization, or other techniques discussed herein.

[0039] As used herein, the term "on-line" refers to a purification or separation step that is performed in such a way that a test sample is placed (e.g., injected) into a system in which various components in the system are operatively linked and, in some embodiments, in fluid communication with one another. In contrast to the term online, the term "off-line" refers to a purification, separation, or extraction that is performed separate from prior and / or subsequent purification or separation and / or analytical steps.

[0040] As used herein, "precision" is expressed as standard deviation (SD) and / or percent coefficient of variation (%CV). "Intra-run precision" is the closeness of agreement between successive measurement results of the same measurement, performed under the same measurement conditions (same analytical run). "Inter-run precision" is the closeness of agreement between independent test results obtained under defined conditions (different analytical runs and / or operators, laboratories, facilities, reagent lots, component equipment, etc.).

[0041] As used herein, a progesterone metabolite is a compound derived from progesterone by a biochemical mechanism. Progesterone sulfate is a progesterone metabolite that has at least one sulfate group.

[0042] As used herein, the terms "purify" or "separate" or derivatives thereof do not necessarily refer to the removal of all materials other than the analyte(s) of interest from a sample matrix. Instead, in some embodiments, the terms purify or separate refer to a procedure that enriches the amount of one or more analytes of interest relative to one or more other components present in the sample matrix. In some embodiments, a "purification" or "separation" procedure can be used to remove one or more components of a sample that may interfere with detection of the analyte, for example, one or more components that may interfere with detection of the analyte by mass spectrometry.

[0043] As used herein, the term "selectivity" refers to the ability of a measurement procedure to accurately measure an analyte of interest without the contribution of other substances that may be found in a sample. Selectivity may be expressed as cross-reactivity and / or response to substances other than the analyte of interest in the presence of the analyte of interest.

[0044] As used herein, "selected reaction monitoring" or "SRM" is a technique in mass spectrometry in which ions of a particular mass are selected in the first stage of a tandem mass spectrometer, and the ion products of a fragmentation reaction of the precursor ion are selected in the second stage of the mass spectrometer. In contrast, "multiple reaction monitoring" or "MRM" is the application of SRM to multiple product ions from one or more precursor ions. For example, in MRM where one or more different precursor ions are formed in the first stage, such ions can be selected sequentially and multiple product ions can be detected. SRM monitors only a single fixed mass window, while MRM rapidly scans multiple narrow mass windows to acquire multiple fragment ion mass trajectories in parallel.

[0045] As used herein, the term "specificity" refers to the ability of a measurement procedure to discriminate between an analyte of interest when present along with substances likely to be found in a sample. Specificity may be expressed as cross-reactivity and / or response rate to substances other than the analyte of interest in the absence of the analyte of interest.

[0046] As used herein, the term "surface-enhanced laser desorption ionization" or "SELDI" refers to a method in which a non-volatile sample is exposed to laser irradiation, thereby desorbing and ionizing the analytes in the sample through various ionization pathways, including photoionization, protonation, deprotonation, and cluster decay. For SELDI, the sample is typically bound to a surface that preferentially retains one or more analytes of interest. Similar to MALDI, this process may also use energy absorbing materials to facilitate ionization.

[0047] As used herein, the term "subject" may include animals. Thus, in some embodiments, samples are obtained from mammals, including but not limited to dogs, cats, horses, rats, and monkeys. In some embodiments, samples are obtained from human subjects. In some cases, the human subject is a pregnant woman. In some embodiments, the subject is a patient, i.e., a living human presenting in a clinical setting for diagnosis, prognosis, or treatment of a disease or condition. In some embodiments, the sample is not a biological sample, but includes non-biological samples, e.g., obtained during the manufacture or laboratory analysis of vitamins, and can be analyzed to determine the composition and / or yield of the manufacturing and / or analytical process.

[0048] As used herein, the term "ULOQ" or "upper limit of quantitation" is the maximum amount of analyte in a sample that can be quantified without dilution. How to Detect Progesterone Sulfate

[0049] Embodiments of the present disclosure relate to methods and systems for the quantitative analysis of progesterone metabolite biomarkers. The present disclosure can be embodied in a variety of ways.

[0050] In one embodiment, a method for determining the presence or amount of a progesterone metabolite in a sample from a subject by mass spectrometry is disclosed, comprising: (a) generating one or more precursor ions from said progesterone metabolites; (b) generating one or more product ions from said one or more precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating said detected ions with the presence or amount of a progesterone metabolite in said sample. In certain embodiments, the method may include: providing a sample suspected of containing at least one progesterone metabolite; optionally chromatographically separating said at least one progesterone metabolite from other components in said sample; using mass spectrometry to generate one or more precursor ions specific to said progesterone metabolites and another product ion derived from said one or more precursor ions; and determining the presence or amount of a progesterone metabolite in said sample.

[0051] In certain embodiments, progesterone metabolite is progesterone sulfate.In various embodiments, progesterone metabolite can include at least one of 5β-pregnane-3α,20α-diol sulfate (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S) and / or 5α-pregnane-3β-ol-20-one sulfate (PM5S); and / or diprogesterone sulfate (such as 5α-pregnane-3α,20α-diol disulfate (PM2DiS) and / or 5β-pregnane-3α,20α-diol disulfate (PM3DiS)). Additional names used interchangeably herein for progesterone metabolites may include: PM2DiS (allopregnanediol disulfate): 5α-pregnane-3α,20α-diol disulfate; PM3S (pregnanediol sulfate): 5β-pregnane-3α,20α-diol sulfate; PM3DiS (pregnanediol disulfate): 5β-pregnane-3α,20α-diol disulfate; PM4S (allopregnanolone sulfate): 5α-pregnane-3α-ol,20-one sulfate; or PM5S (epialopregnanolone sulfate): 5α-pregnane-3β-ol,20-one sulfate.

[0052] In one embodiment, the sample can be measured by tandem mass spectrometry (MS / MS). In certain embodiments, triple quadrupole tandem mass spectrometry can be used. In certain embodiments, multiple reaction monitoring (MRM) can be used, optionally using transition ion summation.

[0053] The analyte (i.e., the progesterone metabolite of interest) may be partially purified before mass spectrometry. Thus, in one embodiment, the sample is subjected to a purification step before the step (a) of generating precursor ions. For example, in certain embodiments, the sample is subjected to protein dilution and / or precipitation. Alternatively, liquid-liquid extraction (LLE) may be used. Alternatively, solid-phase extraction (SPE) may be used.

[0054] In certain embodiments, the sample may be subjected to chromatography for purification. In one embodiment, the chromatography is liquid chromatography (LC) or high performance liquid chromatography (HPLC) or high throughput chromatography (HTLC). Thus, various liquid chromatography separation techniques may be used. For example, the LC step may include one LC separation, or multiple LC separations. In one embodiment, the chromatographic separation includes extraction and analytical liquid chromatography. As discussed herein, in certain embodiments, the analytical chromatography may include high performance liquid chromatography (HPLC). In certain embodiments, high turbulence liquid chromatography (HTLC) (also known as high throughput liquid chromatography) may be used. Additionally and / or alternatively, other chromatographic purification types may be used.

[0055] Also, in certain embodiments, the method of the present disclosure may include multiple liquid chromatography steps. Thus, in certain embodiments, a two-dimensional liquid chromatography (LC) procedure is used. For example, in one embodiment, the method may include transferring a biomarker of interest from an LC extraction column to an analytical column. In one embodiment, the transfer of at least one biomarker of interest from the extraction column to the analytical column is performed by a heart-cutting technique. In another embodiment, the biomarker of interest is transferred from the extraction column to the analytical column by a chromatofocusing technique. Alternatively, the biomarker of interest is transferred from the extraction column to the analytical column by a column switching technique. These transfer steps may be performed manually or may be part of an online system. Optionally, an extraction column may not be used in the methods and systems described herein.

[0056] Thus, in certain embodiments, the method may include the steps of: (a) providing a sample suspected of containing progesterone metabolites; (b) partially purifying the progesterone metabolites in the sample from other components by diluting the sample and / or precipitation of protein; (c) transferring the progesterone metabolites to an analytical column and chromatographically separating the progesterone metabolites in the sample from other components; and (d) analyzing the chromatographically separated progesterone metabolites by mass spectrometry to determine the presence or amount of one or more biomarkers in the test sample. In one embodiment, the mass spectrometry is tandem mass spectrometry.

[0057] In certain embodiments, five distinct progesterone metabolites (e.g., PM3S, PM4S, PM5S, PM2DiS, and PM3DiS) may be measured by liquid chromatography with tandem mass spectrometry detection (LC-MS / MS) after dilution and protein precipitation.

[0058] In certain embodiments, certain progesterone metabolites may be measured together (i.e., simultaneously in the same assay) or separately (i.e., in different assays). For example, in certain embodiments, PM3S is measured separately in an assay ("PM3S" assay). In certain embodiments, monosulfate PM4S and PM5S are measured together in an assay ("MPMS" assay). In certain embodiments, disulfate PM2DiS and PM3DiS are measured together in an assay ("PMDiS" assay). In such embodiments, the three assays may use separate standards, quality control (QC) materials, internal standards, and liquid chromatography tandem mass spectrometry (LC-MS / MS) methods. However, the steps in sample processing may be the same for all three assays.

[0059] The method may include the use of an internal standard. The internal standard may include a progesterone metabolite analyte of interest labeled with a stable isotope. In certain embodiments, the stable isotope may be deuterium (d). Alternatively, other isotopes may be used. For example, in certain embodiments, the internal standard(s) may include at least one of the following: PM3S-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] sulfate); PM5S-d4 (i.e., 5α-pregnane-3β-ol-20-one-[2,2,4,4-d4] sulfate); PM2DiS-d4 (i.e., 5α-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate); and / or PM3DiS-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate). Such standards may be synthesized and / or purchased.

[0060] Thus, in certain embodiments, stable isotope-labeled internal standards of progesterone sulfate (PM3S-d4, PM5S-d4, PM2DiS-d4, and / or PM3DiS-d4) may be added to standards, quality controls, and patient samples (e.g., serum aliquots) to assess and correct the recovery of separate progesterone sulfate from each sample. Standards, control samples, and patient samples are diluted and then subjected to protein precipitation and / or other purification steps. A portion of the sample (i.e., sample, control, and / or standard) may then be concentrated by drying prior to reconstitution.

[0061] The final product from each patient and calibrator can then be analyzed by HPLC with tandem mass spectrometry. In certain embodiments, the sample is injected into an ARIA TX4 system, and the analyte(s) of interest are chromatographically analyzed by an analytical column with gradient separation. An AB SCIEX API5000 triple quadrupole mass spectrometer operating in negative ion electrospray ionization (ESI) mode (Turboionspray) can be used for detection. Alternatively, other types of ionization and / or mass spectrometry methods described herein can be used.

[0062] In certain embodiments, the back-calculated amount of each sample may be determined from a duplicate calibration curve generated by spiking known amounts of progesterone sulfate into a matrix (e.g., 6% bovine serum albumin (BSA)). Analytes and internal standards may be quantified by selected reaction monitoring (SRM) and / or multiple reaction monitoring (MRM). In certain embodiments, ion summation may be used.

[0063] Examples of transitions that may be monitored are listed in Table 1. In one embodiment, the LC-MS / MS acquisition may include the transitions monitored in Tables 3-5. Alternatively, other transitions may be monitored. As known in the art, transitions may vary slightly from machine to machine and are determined during instrument tuning. For example, in certain embodiments, selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) may be used to select parent (precursor) ions and product (i.e., daughter or fragment) ions. Examples of MRM scans for PM3S, MPMS (PM4S and PM5S), and PMDiS (PM2DiS and PM3DiS) that select for parent-daughter (i.e., precursor-product or precursor-fragment) ions are shown in Figures 4-6, respectively. Thus, in certain embodiments, PM3S is measured by MRM using the analyte peak for the 399.400→97.100 transition as shown in Figure 4. Additionally and / or alternatively, in certain embodiments, PM4S and PM5S are measured by MRM using the analyte peak for the transition 397.3→97.0 for PM5S and the analyte peak for the transition 397.2→97.0 for PM4S, as shown in Figure 5. Additionally and / or alternatively, in certain embodiments, PM2DiS and PM3DiS are measured by MRM using ion summation. Therefore, as shown in FIG. 6, the sum of the transitions 479.098→381.2+479.099→381.2+479.100→381.2+479.101→381.2+479.102→381.2 may be used to detect PM2DiS, and the sum of the transitions 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.1 may be used to detect PM3DiS. Table 1 [Table 1]

[0064] A variety of samples may be used. In some embodiments, the biological sample may include blood, serum, plasma, urine, nasopharyngeal swab, or saliva. In certain embodiments, the sample is serum. For example, serum may be collected in red top tubes or SST tubes and frozen. Serum may be collected in purple top (EDTA) tubes or green top (heparin) tubes. In certain embodiments, a minimum of 1 mL of serum may be used, or 2.5 mL of serum (e.g., for pediatric subjects) or 5 mL of serum (for adults).

[0065] In certain embodiments, using either plasma or serum samples, the lower limit of detection (LLOD) of a 100 μL sample aliquot for each of PM3S, PM4S, PM5S, PM2DiS, and PM3DiS is 1 ng / mL. Lower volumes of samples may be used. Thus, in certain embodiments, a volume of 20 μL may be used for PM3S, PM2DiS, and PM3DiS, and a volume of 10 μL may be used for PM4S and PM5S.

[0066] The method may include detection of progesterone sulfate over an analytical measurement range (AMR) (i.e., LLOQ-ULOQ) of 1-500 ng / mL for PM3S, PM4S, PM5S PM2DiS, and PM3DiS. PM3S, PM2DiS, and PM3DiS can be diluted up to 5-fold for measurement of a maximum amount of 2,500 ng / mL, while PM4S and PM5S can be diluted up to 10-fold for measurement of a maximum amount of 5,000 ng / mL. In certain embodiments, the ULOQ for each progesterone sulfate is about 500 ng / mL and the LLOQ is 1 ng / mL.

[0067] An example of a method of the present disclosure is shown in Figure 1. Thus, in one embodiment, the method 100 can include a step 102 of providing a biological sample (e.g., a serum or plasma sample suspected of containing progesterone sulfate metabolites).

[0068] An internal standard may then be added to the sample 104. In certain embodiments, stable isotope-labeled internal standards of progesterone sulfate (PM3S-d4, PM5S-d4, PM2DiS-d4, and / or PM3DiS-d4) are added to standards, quality controls, and patient serum or plasma aliquots to assess and correct for distinct progesterone sulfate recoveries from each sample.

[0069] The sample (and optional standards and control samples) may then be diluted 106 and reagents added to precipitate proteins 108. For example, in certain embodiments, the sample is diluted by addition of an internal standard (IS) in 6% bovine serum albumin (BSA) and then acetonitrile is added to precipitate proteins. A portion of the sample extract may then be concentrated by drying the sample prior to reconstitution.

[0070] With further reference to Figure 1, the method may further include liquid chromatography as a means for separating progesterone sulfate from other components in the sample. In certain embodiments, a single step of HPLC is used 110. Alternatively, in some embodiments, two liquid chromatography steps are used. For example, the method may include liquid chromatography on a first extraction column (not shown) followed by transfer to a second analytical column (e.g., HPLC). Alternatively, HTLC may be used.

[0071] Various analytical columns known in the art may be used to obtain satisfactory purification, if desired. In certain embodiments, the analytical column may include particles with an average particle size of about 2-3 μm (e.g., 2.6 μm). In some embodiments, the analytical column is a functionalized silica or polymer-silica hybrid, or a polymer particle or monolithic silica stationary phase (such as a phenyl-hexyl functionalized analytical column). Alternatively, in certain embodiments, an Aria TX4 HTLC system (Cohesive Technologies, MA) is used.

[0072] The separated analytes are then analyzed by mass spectrometry, in one embodiment using triple quadrupole tandem mass spectrometry (MS / MS), whereby one or more precursor ions are selected 112 after ionization, and the one or more precursor ions are subjected to further fragmentation to generate one or more product ions 114, whereby the one or more product ions are used for detection.

[0073] The analytes of interest can then be quantified based on the amount of characteristic transitions measured by the tandem MS116. In some embodiments, the tandem mass spectrometer includes a triple quadrupole mass spectrometer. In certain embodiments, an Applied Biosystems API5000 or API5500 can be used in negative ESI mode. In some embodiments, the tandem mass spectrometer is operated in positive ion atmospheric pressure chemical ionization (APCI) mode. In some embodiments, the analytes and internal standards are quantified in selected reaction monitoring mode (SRM). Alternatively, other ionization methods such as using inductively coupled plasma, or MALDI, or SELDI, or APPI, can be used for ionization.

[0074] In some embodiments, the back-calculated amount of each analyte in each sample may be determined by comparing the response or response ratio of the unknown sample using the internal standard to a calibration curve generated by spiking known amounts of purified analyte into a standard test sample (e.g., charcoal-stripped human serum or BSA). In one embodiment, calibrators are prepared at known concentrations and analyzed to obtain the response or response ratio using the internal standard to a concentration calibration curve.

[0075] The disclosed method can quantify progesterone sulfate at physiologically relevant levels.As discussed herein, progesterone sulfate level can be an important indicator of the effectiveness of various therapeutic compounds for reducing pregnancy complications such as intrahepatic cholestasis of pregnancy (ICP) and complications that may result from the aforementioned complications, such as fetal death, preterm birth, and / or iatrogenic preterm birth.Therefore, in some embodiments, progesterone sulfate amount is used to distinguish whether skin pruritus of pregnancy is an early sign of (ICP) or is caused by benign pruritus of pregnancy in subjects. In one embodiment, the method can report serum concentration levels of PM3S, PM4S, PM5S, PM2DiS, and / or PM3DiS as follows: PM3S: 36.0-221 ng / mL; and / or PM4S: 44.7-725 ng / mL; and / or PM5S: 11.2-223; PM2DiS: 37.4-505 ng / mL; and / or PM3DiS: 4.912-78.3 ng / mL. System for Analyzing Progesterone Sulfate Biomarkers

[0076] In other embodiments, the present disclosure includes a system for carrying out any of the steps of the method disclosed herein.For example, in certain embodiments, a system for determining the presence or amount of one or more progesterone metabolites in a sample is disclosed.In certain embodiments, the system for determining the presence or amount of a progesterone metabolite may include a station and / or component for providing a test sample that is believed to contain a progesterone metabolite of interest; a mass spectrometer station and / or component for fragmenting the progesterone metabolite of interest to generate at least one precursor ion and at least one product ion; and a station and / or component for determining the presence or amount of the progesterone metabolite of interest in said sample.In certain embodiments, the system may include a station and / or component for partially purifying the progesterone metabolite of interest in the sample from other components.In addition, and / or alternatively, the system may further include a station and / or component for chromatographically separating the progesterone metabolite of interest in the sample from other components. For example, the system may include a station and / or component for providing a test sample; optionally, a station and / or component for partially purifying the progesterone metabolites in the sample from other components; optionally, a station and / or component for chromatographically separating the progesterone metabolites in the sample from other components; a station and / or component for mass spectrometry to generate one or more precursor ions and one or more product ions from the progesterone metabolites; and a station and / or component for analyzing the mass spectrum to determine the presence or amount of the progesterone metabolites in the test sample. In some embodiments, certain stations and / or components are combined into a single station and / or component.

[0077] In certain embodiments, progesterone metabolite is progesterone sulfate.In various embodiments, progesterone metabolite can include at least one of 5β-pregnane-3α,20α-diol sulfate (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S) and / or 5α-pregnane-3β-ol-20-one sulfate (PM5S); and / or diprogesterone sulfate (such as 5α-pregnane-3α,20α-diol disulfate (PM2DiS) and / or 5β-pregnane-3α,20α-diol disulfate (PM3DiS)).

[0078] In one embodiment, the sample can be measured by tandem mass spectrometry. In certain embodiments, triple quadrupole tandem mass spectrometry (MS / MS) can be used. In certain embodiments, selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) can be used, optionally using transition ion summation.

[0079] In certain embodiments, at least one of the stations may be controlled by a computer and / or a computer program product tangibly embodied in a non-transitory machine-readable storage medium. Thus, in certain embodiments, a system may include a computer program product tangibly embodied in a non-transitory machine-readable storage medium that includes instructions configured to control any of the stations and / or components of the system.

[0080] The system may include a station and / or component for adding a stable isotope-labeled internal standard(s). In certain embodiments, a stable isotope-labeled internal standard of progesterone sulfate (e.g., PM3S-d4, PM5S-d4, PM2DiS-d4, and / or PM3DiS-d4) is added to aliquots of standards, quality controls, and patient serum or plasma to assess and correct for the separate recovery of progesterone sulfate from each sample.

[0081] In certain embodiments, the system may also include a station and / or component for partial purification of at least one progesterone metabolite of interest in the sample from other components prior to the station for liquid chromatographic separation. In certain embodiments, the station and / or component for partial purification may include a station or component for sample dilution, liquid-liquid extraction, solid-phase extraction, and / or protein precipitation. For example, the station and / or component for partial purification may include reagents for dilution and / or protein precipitation.

[0082] In certain embodiments, the system may include stations and / or components for chromatographically separating progesterone metabolites from other components in the sample. In various embodiments, the chromatography is liquid chromatography (LC) or high performance liquid chromatography (HPLC) or high throughput chromatography (HTLC). The LC step may include one LC separation, or multiple LC separations. In one embodiment, the chromatographic separation includes extraction and analytical liquid chromatography. As discussed herein, in certain embodiments, the analytical chromatography may include high performance liquid chromatography (HPLC). In certain embodiments, high turbulence liquid chromatography (HTLC) (also known as high throughput liquid chromatography) may be used. Additionally and / or alternatively, other types of purification may be used.

[0083] As described herein, in some embodiments, an isotopically labeled internal standard or standards may be added to the sample. An isotopically labeled internal standard or standards may be added before the partial purification step to normalize the loss of analytes (e.g., progesterone metabolites) that may occur during the procedure. Thus, the station and / or components for partial purification may include a hood or other safety features necessary for working with solvents and / or isotopically labeled materials.

[0084] The stations or components for sample dilution, protein precipitation, and addition of internal standards may each be separate stations or may be combined into one or two stations or components.

[0085] In one embodiment, the station and / or component for chromatographic separation includes at least one device for performing liquid chromatography (LC). In one embodiment, the station and / or component for liquid chromatography may include a column for analytical chromatography. For example, in certain embodiments, the chromatography may include high performance liquid chromatography (HPLC). Alternatively, in some embodiments, the chromatography may include HTLC. In some embodiments, the chromatographic separation may also include extraction chromatography prior to analytical liquid chromatography.

[0086] A variety of analytical columns known in the art may be used as part of the chromatographic station to provide good purification, if desired. In certain embodiments, the analytical column may include particles with an average particle size of about 2-3 μm (i.e., 2.6 μm). In some embodiments, the analytical column is a functionalized silica or polymer-silica hybrid, or a polymer particle or monolithic silica stationary phase (such as a phenyl-hexyl functionalized analytical column). Alternatively, in certain embodiments, the station may include an Aria TX4 HTLC system (Cohesive Technologies, MA).

[0087] In certain embodiments, the system of the present disclosure may include multiple liquid chromatography steps. Thus, in certain embodiments, a two-dimensional liquid chromatography (LC) procedure is used. For example, in one embodiment, the system of the present disclosure may include a station and / or components for transferring a biomarker of interest from an LC extraction column to an analytical column. In one embodiment, the transfer of at least one biomarker of interest from the extraction column to the analytical column is performed by a heart-cutting technique. In another embodiment, the biomarker of interest is transferred from the extraction column to the analytical column by a chromatofocusing technique. Alternatively, the biomarker of interest is transferred from the extraction column to the analytical column by a column switching technique. These transfer steps may be performed manually or may be part of an online system. Optionally, an extraction column may not be used in the methods and systems described herein.

[0088] In certain embodiments, the station and / or components for mass analysis include a tandem mass spectrometer. In some embodiments, the tandem mass spectrometer includes a triple quadrupole mass spectrometer. In certain embodiments, an Applied Biosystems API5000, API5500, or Agilent 7000 triple quadrupole mass spectrometer may be used in negative ESI mode. In some embodiments, the tandem mass spectrometer is operated in positive ion atmospheric pressure chemical ionization (APCI) mode. In some embodiments, the analyte and internal standard are quantified in selected reaction monitoring mode (SRM). Alternatively, other ionization methods such as using inductively coupled plasma, or MALDI, or SELDI, or APPI, may be used for ionization.

[0089] Figure 2 provides a diagram of an embodiment of a system of the present disclosure. As shown in Figure 2, the system 200 may include a station and / or component 202 for aliquoting a sample that may contain a progesterone metabolite of interest into sampling containers. In one embodiment, the sample is aliquoted into one or more containers to facilitate liquid-liquid extraction or dilution of the sample. The station and / or component for aliquoting may include a container for discarding or storing a portion of the biological sample not used in the analysis.

[0090] The system may further include a station and / or component 204 for adding an internal standard to the sample. In one embodiment, the internal standard comprises at least one of the progesterone metabolites of interest labeled with a non-natural isotope. Thus, the station or component for adding the internal standard may include safety features to facilitate the addition of the isotopically labeled internal standard solution to the sample.

[0091] The system may also, in some embodiments, include station(s) and / or component(s) 208 for partial purification of the progesterone metabolite of interest. Thus, in certain embodiments, the system may include stations or components 208 for sample dilution and / or protein precipitation. Alternatively, it may include stations and / or components for other types of sample purification, such as liquid-liquid extraction or solid-phase extraction.

[0092] The system may also include a station and / or component 210 for liquid chromatography (LC) of the sample. As described herein, in one embodiment, the station and / or component for liquid chromatography may include an HPLC (or HTLC) column. The station for liquid chromatography may include a column including a stationary phase, and a container or vessel including a solvent used as a mobile phase. In one embodiment, the mobile phase includes a gradient of acetonitrile, ammonium formate, and water or other miscible solvent with a volatile buffer. Thus, in one embodiment, the station and / or component for chromatography may include appropriate lines and valves to regulate the amount of separate solvents applied to a column or columns. The station and / or component may also include a means for removing and discarding fractions that do not include the biomarker of interest. In one embodiment, fractions that do not include the biomarker of interest are continuously removed from the column and sent to a waste container for decontamination and discarded. In certain embodiments, the station and / or component may include an Aria TX4 HTLC system (Cohesive Technologies, MA).

[0093] The system may also include a station and / or component 212 for mass spectrometry. In one embodiment, the station or component for mass spectrometry includes tandem mass spectrometry (MS / MS). The system may also include a station and / or component for characterization and / or quantification of analytes. The station and / or component for characterization and / or quantification may include a station and / or component 216 for data analysis of LC-MS / MS results. In one embodiment, the analysis includes both identification and quantification of the progesterone metabolite(s) of interest.

[0094] As illustrated in FIG. 2, any of the stations and / or components of the system may be automated, robotically controlled, and / or controlled at least in part by a computer 300 and / or programmable software. For example, the station(s) and / or component(s) for LC-MS / MS and / or data analysis may be controlled at least in part by a computer. Thus, the system may include a computer program product tangibly embodied in a non-transitory machine-readable storage medium that includes instructions configured to cause the system or any part of the system (e.g., station or component) to operate and / or perform one or more steps of the method of any of the disclosed embodiments. In some embodiments, a system is provided that includes one or more data processors and a non-transitory computer-readable storage medium that includes instructions that, when executed on said one or more data processors, cause said one or more data processors to perform some or all of one or more of the methods or processes disclosed herein and / or operate any of the parts of the system disclosed herein.

[0095] For example, a system is disclosed that includes one or more data processors and a non-transitory computer-readable storage medium that includes instructions that, when executed on said one or more data processors, cause said one or more data processors to perform operations to direct at least one of the following steps: providing a sample suspected of containing at least one progesterone metabolite; optionally chromatographically separating said at least one progesterone metabolite in said sample from other components; generating at least one precursor ion and at least one product ion specific for said progesterone metabolite using tandem mass spectrometry; and determining the presence or amount of progesterone metabolite in said sample. Additionally and / or alternatively, in certain embodiments, a system is disclosed that includes one or more data processors and a non-transitory computer-readable storage medium that includes instructions that, when executed on said one or more data processors, cause said one or more data processors to perform operations to direct at least one of: (a) generating one or more precursor ions from said progesterone metabolites; (b) generating one or more product ions of said precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating said detected ions with the presence or amount of progesterone metabolites in said sample.

[0096] Also disclosed is a computer program product tangibly embodied in a non-transitory machine-readable storage medium that includes instructions configured to operate any of the components or stations of the disclosed system and / or perform one or more steps of the method of any of the disclosed embodiments.For example, in certain embodiments, the computer program product tangibly embodied in a non-transitory machine-readable storage medium includes instructions configured to cause one or more data processors to perform operations to direct at least one of the following steps: preparing a sample believed to contain at least one progesterone metabolite; optionally, chromatographically separating the at least one progesterone metabolite in the sample from other components; using tandem mass spectrometry to generate at least one precursor ion and at least one product ion specific to the progesterone metabolite; and determining the presence or amount of the progesterone metabolite in the sample. In certain embodiments, a non-transitory computer-readable storage medium is disclosed that includes instructions that, when executed on one or more data processors, cause the one or more data processors to perform operations to direct at least one of: (a) generating precursor ions from said progesterone metabolites; (b) generating one or more product ions of said precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating said detected ions with the presence or amount of progesterone metabolites in said sample.

[0097] The systems and computer products may perform any of the methods disclosed herein. One or more of the embodiments described herein may be implemented using a program module, engine, or component. A program module, engine, or component may include a program, subroutine, part of a program, or software or hardware component that can perform one or more of the presented tasks or functions. As used herein, a module or component may exist on a hardware component independent of other modules or components. Alternatively, a module or component may be a shared element or process of other modules, programs, or machines.

[0098] FIG. 3 shows a block diagram of an analytical system 300 used for detection and / or quantification of progesterone metabolites. As illustrated in FIG. 3, various subsystems of the analytical system of various embodiments may be implemented using modules, engines, or components (e.g., programs, codes, or instructions) executable by one or more processors. The modules, engines, or components may be stored in a non-transitory computer medium. If necessary, one or more of the modules, engines, or components may be loaded into a system memory (e.g., RAM) and executed by one or more processors of the analytical system. The example shown in FIG. 3 shows modules, engines, or components for implementing a method or operating any of the systems of the present disclosure.

[0099] Thus, FIG. 3 illustrates an exemplary computing device 300 suitable for use with the systems and methods of the present disclosure. The exemplary computing device 300 includes a processor 305 in communication with memory 310 and other components of the computing device 300 using one or more communication buses 315. The processor 305 is configured to execute processor-executable instructions stored in the memory 310 to perform one or more methods or operate one or more stations for detecting progesterone metabolite levels according to different examples (such as those in FIGS. 1-2 and 4-6 or those disclosed elsewhere herein). In this example, the memory 310 may store processor-executable instructions 325 that can analyze 320 results for the sample as discussed herein.

[0100] The computing device 300 may also include one or more user input devices 330 (such as a keyboard, mouse, touch screen, microphone, etc.) for accepting user input, in this example. The computing device 300 may also include a display 335 for providing visual output to a user, such as a user interface. The computing device 300 may also include a communication interface 340. In some examples, the communication interface 340 may be capable of communicating using one or more networks, including a local area network ("LAN"); a wide area network ("WAN") (such as the Internet); a metropolitan area network ("MAN"); a point-to-point connection or a peer-to-peer connection, etc. Communication with other devices may be performed using any suitable network protocol. For example, one suitable network protocol may include the Internet Protocol ("IP"), Transmission Control Protocol ("TCP"), User Datagram Protocol ("UDP"), or a combination thereof (such as TCP / IP or UDP / IP).

[0101] In some embodiments, one or more of the purification or separation steps can be performed "online". The online system may include an autosampler for taking an aliquot of a sample from one container and transferring such an aliquot into another container. For example, the autosampler may be used to transfer a sample after extraction on an LC extraction column. Additionally or alternatively, the online system may include one or more injection ports for injecting the fraction isolated from the LC extraction column onto an LC analytical column. Additionally or alternatively, the online system may include one or more injection ports for injecting the LC-purified sample into an MS system. Thus, the online system may include one or more columns, including but not limited to an extraction column and / or an analytical column. Additionally or alternatively, the system may include a detection system (e.g., a mass spectrometer system). The online system may also include one or more pumps; one or more valves; and plumbing as required. In such "on-line" systems, test samples and / or analytes of interest can be passed from one component of the system to another without exiting the system (e.g., without being collected and then discarded in another component of the system).

[0102] In some embodiments, the online purification or separation method can be automated. In such embodiments, once the process is set up and started, the steps can be performed without the need for operator intervention. For example, in one embodiment, the system or parts of the system can be controlled by one or more computers 300. Thus, in certain embodiments, the present disclosure can include software for controlling various components of the system, including pumps, valves, autosamplers, and the like. Such software can be used to optimize the extraction process with precise timing of addition and flow rates of samples and solutes.

[0103] Although some or all of the systems, including the steps and stations in the method, may be online, in certain embodiments, some or all of the steps may be performed "offline." In such offline procedures, the analytes of interest are typically separated from other components in the sample matrix, for example, on an extraction column or by liquid / liquid extraction, and then recovered for subsequent introduction into another chromatographic or detector system. Offline procedures typically require manual intervention on the part of an operator.

[0104] As described herein, liquid chromatography may include high turbulence liquid chromatography or high throughput liquid chromatography (HTLC) in certain embodiments. See, for example, Zimmer et al., J. Chromatogr. A 854:23-35 (1999); see also U.S. Patent Nos. 5,968,367; 5,919,368; 5,795,469; and 5,772,874. Traditional HPLC analysis relies on column packing, which makes laminar flow of the sample through the column the basis for separation of the analytes of interest from the sample. In such columns, separation is a diffusion process. The turbulence provided by such columns and methods of HTLC can enhance mass transfer rates and improve separation characteristics. In some embodiments, high turbulence liquid chromatography (HTLC) may be used alone or in combination with one or more purification methods to purify biomarkers of interest prior to mass spectrometry. In such an embodiment, the sample may be extracted using an HTLC extraction cartridge that captures the analyte, and then eluted and chromatographed on a second HTLC column or an analytical HPLC column prior to ionization. The steps involved in these chromatographic procedures may be linked in an automated fashion, minimizing the need for operator intervention during purification of the analyte. Also, in some embodiments, the use of high turbulence liquid chromatographic sample preparation methods may eliminate the need for other sample preparation methods, including liquid-liquid extraction. Thus, in some embodiments, the test sample (e.g., bodily fluid) may be placed (e.g., injected) directly into a high turbulence liquid chromatographic system.

[0105] For example, in a typical high turbulence or turbulent flow liquid chromatography system, a sample may be injected directly into a narrow (e.g., 0.5 mm to 2 mm ID x 20 to 50 mm length) column packed with large (e.g., >25 micron) particles. When a flow rate (e.g., 3 to 500 mL / min) is applied to the column, the relatively narrow width of the column increases the velocity of the mobile phase. The large particles present in the column prevent back pressure due to acceleration and promote the formation of intermittent vortices between the particles, thereby obtaining turbulent flow within the column.

[0106] In high turbulence liquid chromatography, analyte molecules may bind to particles quickly and typically do not spread (i.e., diffuse) along the length of the column. This reduction in longitudinal diffusion typically results in better and more rapid separation of the analyte of interest from the sample matrix. Additionally, turbulent flow within the column typically reduces friction of the molecules as they pass through the particles. For example, in traditional HPLC, molecules traveling closest to the particles move slower along the column than molecules flowing in the center of the paths between the particles. This difference in flow rates causes the analyte molecules to spread along the length of the column. When turbulent flow occurs within the column, friction on the molecules from the particles becomes negligible, and longitudinal dispersion is reduced.

[0107] In certain embodiments, the mass spectrometer uses a "quadrupole" system. In a "quadrupole" or "quadrupole ion trap" mass spectrometer, ions in an oscillating radio frequency (RF) electric field are subjected to a direct current (DC) potential applied between the electrodes, the amplitude of the RF signal, and a force proportional to m / z. The voltage and amplitude can be selected such that only ions with a particular m / z travel longitudinally through the quadrupole, while all other ions are ejected from the quadrupole. Thus, a quadrupole device can act as both a "mass filter" and a "mass detector" for ions injected into the device.

[0108] Certain embodiments use tandem mass spectrometry, or "MS / MS." MS / MS techniques are useful for the analysis of complex mixtures, particularly biological samples, in part because the selectivity of MS / MS can minimize the need for extensive cleanup of samples prior to analysis.

[0109] In one embodiment, the disclosed methods and systems use triple quadrupole MS / MS. A triple quadrupole MS / MS instrument typically consists of two quadrupole mass filters separated by a fragmentation means. In one embodiment, the instrument may include a quadrupole mass filter operated in RF-only mode as an ion storage device or an ion transmission device. In one embodiment, the quadrupole may further include a collision gas at a pressure between 1 and 10 millitorr. Many other types of "hybrid" tandem mass spectrometers are also known and may be used in the disclosed methods and systems, including various combinations of magnetic sector analyzers and quadrupole filters. These hybrid instruments often include a high-resolution magnetic sector analyzer as either or both of the mass filters (i.e., an analyzer that includes both a magnetic sector and an electrostatic sector arranged in a double focusing combination). The use of a high-resolution mass filter can be very effective in reducing chemical noise to very low levels.

[0110] For the methods and systems of the present disclosure, ions can be generated using a variety of methods, including, but not limited to, electron ionization, chemical ionization, fast electron impact, field desorption, and matrix-assisted laser desorption ionization ("MALDI"), surface-enhanced laser desorption ionization ("SELDI"), photon ionization, electrospray ionization, and inductively coupled plasma.

[0111] Embodiments of the present disclosure may offer certain advantages: In certain embodiments, the methods and systems of the present disclosure may provide greater sensitivity than previously achievable for many analytes measured.

[0112] Additionally, embodiments of the disclosed methods and systems allow for previously unachieved rapid processing of many analytes measured. For example, using the disclosed methods and systems, multiple samples can be analyzed for the analyte progesterone sulfate using a multiplex system consisting of 96-well plates and four LC-MS / MS systems with significantly higher throughput.

[0113] Another advantage is that the specificity and sensitivity provided by the disclosed method and system allows for the analysis of analytes from various biological materials. For example, the disclosed LC-MS / MS method can be applied to the quantification of analytes of interest in complex biological sample matrices, including but not limited to blood, serum, plasma, urine, saliva, and nasopharyngeal swabs. Therefore, the disclosed method and system are suitable for clinical application and / or clinical trials.

[0114] As a further potential advantage, in certain embodiments, the disclosed systems and methods provide an approach to address isobaric interferences, sample content variations (including hemolytic and lipemic samples) while achieving the lower limit of quantification (LOQ) (mg / dL) of the target analyte. Thus, embodiments of the disclosed methods and systems are capable of quantitative, sensitive, and specific detection of clinical biomarkers used in out-of-bed diagnosis of disorders. EXAMPLES

[0115] Working Example The present disclosure may be further understood by reference to the following non-limiting examples. Example 1 - Assay Method

[0116] Five separate progesterone sulfates (PM3S, PM4S, PM5S, PM2DiS, and PM3DiS) were measured by liquid chromatography with tandem mass spectrometry detection (LC-MS / MS) after dilution and protein precipitation. PM3S was measured separately in one assay (PM3S). PM4S and PM5S were measured together in one assay (MPMS), while PM2DiS and PM3DiS were measured together in one assay (PMDiS). The three assays use separate standards, QC materials, internal standards, and LCMS methods. Sample processing steps are identical for all three assays.

[0117] Stable isotope-labeled internal standards of progesterone sulfate (PM3S-d4, PM5S-d4, PM2DiS-d4, and / or PM3DiS-d4) were added to standard, quality control, and patient serum aliquots to assess and correct for distinct progesterone sulfate recovery from each sample. Standards, control samples, and patient serum were diluted and then protein precipitation was performed. Portions of sample extracts were concentrated by drying the samples before reconstitution. Final products from each patient and calibrator were analyzed by HPLC with tandem mass spectrometry. All samples were injected into an ARIA TX4 system and chromatographic analysis of the analyte(s) of interest was performed by analytical column with gradient separation. An AB SCIEX API5000 triple quadrupole mass spectrometer operated in negative ion electrospray ionization (ESI) mode (Turboionspray) was used for detection.

[0118] The back-calculated amount of analyte in each sample was determined from duplicate calibration curves generated by spiking known amounts of progesterone sulfate in 6% BSA. Analytes and internal standards were quantified in selected reaction monitoring (SRM) mode with ion summation where required. Transitions monitored are listed in the table below. Note that transitions may vary slightly from machine to machine and are determined during instrument calibration. Example 2 - Validation of Progesterone Sulfate by LC-MS / MS Assay

[0119] Chromatographic assay-validation runs include quality controls (QCs) at a minimum of three concentration levels (low, medium, and high).

[0120] Calibration pass / fail criteria - The calibration curve has a minimum of six non-zero concentration levels and a blank. Readback concentrations must be within 15% of the nominal concentration (20% at the LLOQ) at at least 75% of the aforementioned levels.

[0121] QC pass / fail criteria - At least 2 / 3 of the QCs are within ±15% of the target value; at least 50% of the QCs at each concentration level are within ±15% of the target value.

[0122] Short-term storage, long-term storage, and freeze-thaw stability - Serum stored under the following conditions is acceptable for use for analysis of PM3S, PM4S, PM5S, PM2DiS, and PM3DiS concentrations: frozen (below -10°C and below -55°C): 27 days; refrigerated (2-8°C): 14 days; room temperature (15-30°C): 14 days; or freeze-thaw cycles (below -10°C): 6 cycles (total of 7 thaws). Long-term storage for frozen serum (below -10°C) is 27 days and samples may be shipped frozen on dry ice. Reference range

[0123] To establish reference intervals, serum samples from 120 pregnant women were analyzed, and all samples were used for reference range evaluation. Separate serum (SST) samples were collected from women ranging from 15 to 24 weeks of gestation for AFP Tetra analysis. The reference intervals for PM3S, PM4S, PM5S, PM2DiS, and PM3DiS concentrations in serum as determined by the 97.5th percentile are listed below: PM3S: 36.0-221ng / mL PM4S: 44.7-725ng / mL PM5S: 11.2-223ng / mL PM2DiS: 37.4-505ng / mL PM3DiS: 4.912-78.3ng / mL

[0124] Exemplary scans are shown in Figures 4-6. In these experiments, multiple reaction monitoring was used to select the appropriate transitions. PM3S was monitored separately in one assay (PM3S) (Figure 4). PM4S and PM5S were measured together in one assay (Figure 5). PM2DiS and PM3DiS were measured together in one assay (Figure 6). Ion summation was used for analysis and measurement of PM2DiS and PM3DiS).

[0125] The results are summarized in Table 2, where the analytes that passed the pass / fail criteria are indicated in the analyte column. Table 2 [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] Example 3 - LC-MS / MS Acquisition Method

[0126] Tables 3-5 show the analyte acquisition methods used for PM3S (Table 3), PM4S and PM5S (MPMS) (Table 4), PM2DiS and PM3DiS (PMDiS) (Table 5). The results of such scans are shown in Figure 4 (PM3S), Figure 5 (MPMS), and Figure 6 (PMDiS). As used in Tables 3-5, IS refers to the isotopically labeled standards described herein. 1, 2, and 3 (as well as subdesignators A, B, C, and D) indicate different transitions monitored that may or may not be used for assay quantification. Table 3-PM3S acquisition method [Table 3] Table 4 - MPMS Analyte Acquisition Method [Table 4] Table 5 - PMDiS acquisition method [Table 5-1] [Table 5-2] Example 4 - Exemplary embodiment of the preferred method and system

[0127] As used hereinafter, any range of reference numbers for methods or systems will be understood to refer to one reference number for each of the methods or systems individually (e.g., "exemplary embodiments 1-4 will be understood as exemplary embodiments 1, 2, 3, or 4").

[0128] Exemplary embodiment 1 is a method for determining the presence or amount of a progesterone metabolite in a sample from a subject by mass spectrometry, comprising: (a) generating one or more precursor ions from said progesterone metabolites; (b) generating one or more product ions from said one or more precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating said detected ions with the presence or amount of a progesterone metabolite in said sample.

[0129] Exemplary embodiment 2 is the method of any preceding or following exemplary embodiment, wherein the progesterone metabolite is progesterone sulfate.

[0130] Exemplary embodiment 3 is the method of any preceding or following exemplary embodiment, wherein the progesterone sulfate comprises at least one of 5β-pregnane-3α,20α-diol (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S); 5α-pregnane-3β-ol-20-one sulfate (PM5S); 5α-pregnane-3α,20α-diol disulfate (PM2DiS); or 5β-pregnane-3α,20α-diol disulfate (PM3DiS).

[0131] Exemplary embodiment 4 is the method of any preceding or following exemplary embodiment, where PM3S is measured individually, PM4S and PM5S are measured simultaneously, and PM2DiS and PM3DiS are measured simultaneously.

[0132] Exemplary embodiment 5 is the method of any preceding or following exemplary embodiment, wherein the mass spectrometry is tandem mass spectrometry.

[0133] Exemplary embodiment 6 is the method of any preceding or following exemplary embodiment, wherein the tandem mass spectrometry is triple quadrupole tandem mass spectrometry.

[0134] Exemplary embodiment 7 is a method of any preceding or following exemplary embodiment, wherein selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) optionally with ion summation is used to select precursor ions and / or product ions.

[0135] Exemplary embodiment 8 is the method of any preceding or following exemplary embodiment, wherein PM3S is measured by MRM using the analyte peak for the transition 399.400→97.100.

[0136] Exemplary embodiment 9 is the method of any preceding or following exemplary embodiment, wherein PM4S and PM5S are measured separately or together by MRM using the analyte peak for the transition 397.3→97.0 for PM5S and the analyte peak for the transition 397.2→97.0 for PM4S.

[0137] Exemplary embodiment 10 is a method of any preceding or following exemplary embodiment, where PM2DiS and / or PM3DiS are measured by MRM using ion summation.

[0138] Example embodiment 11 is a method of any preceding or following example embodiment, where a sum of the transitions 479.098→381.2+479.099→381.2+479.100→381.2+479.101→381.2+479.102→381.2 is used for detection of PM2DiS.

[0139] Example embodiment 12 is a method of any preceding or following example embodiment, where a sum of the transitions 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.1 may be used for detection of PM3DiS.

[0140] Exemplary embodiment 13 is the method of any preceding or following exemplary embodiment, wherein the sample is subjected to a purification step prior to the initial fragmentation step (a).

[0141] Exemplary embodiment 14 is the method of any preceding or following exemplary embodiment, wherein the purification step comprises chromatography.

[0142] Exemplary embodiment 15 is the method of any preceding or following exemplary embodiment, wherein the chromatography comprises high performance liquid chromatography (HPLC) or high throughput liquid chromatography (HTLC).

[0143] Exemplary embodiment 16 is the method of any preceding or following exemplary embodiment, further comprising at least one of diluting the sample and / or protein precipitation prior to chromatography.

[0144] Exemplary embodiment 17 is the method of any preceding or following exemplary embodiment, further comprising the addition of a stable isotope labeled internal standard.

[0145] Exemplary embodiment 18 is the method of any preceding or following exemplary embodiment, wherein the stable isotope-labeled internal standard comprises at least one of PM3S-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] sulfate); PM5S-d4 (i.e., 5α-pregnane-3β-ol-20-one-[2,2,4,4-d4] sulfate); PM2DiS-d4 (i.e., 5α-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate); and / or PM3DiS-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate).

[0146] Exemplary embodiment 19 is the method of any preceding or following exemplary embodiment, wherein the sample is serum or plasma.

[0147] Exemplary embodiment 20 is the method of any preceding or following exemplary embodiment, wherein the LLOQ for progesterone sulfate is 1 ng per 100 μL of sample.

[0148] Exemplary embodiment 21 is the method of any preceding or following exemplary embodiment, wherein the ULOQ of progesterone sulfate is 500 ng per 100 μL sample.

[0149] Exemplary embodiment 22 is the method of any preceding or following exemplary embodiment, wherein the amount of progesterone sulfate is used to distinguish whether cutaneous pruritus of pregnancy is an early sign of (ICP) or is due to benign pruritus of pregnancy in a subject.

[0150] Exemplary embodiment 23 is a system for determining the presence or amount of a progesterone metabolite in a test sample, said system including a station and / or component for providing a test sample suspected of containing a progesterone metabolite of interest; a mass spectrometry station and / or component for generating one or more precursor ions, generating one or more product ions from said one or more precursor ions, and fragmenting said progesterone metabolite of interest to determine the amount of at least one of said precursor ions or said at least one product ion; and a station and / or component for determining the presence or amount of a progesterone metabolite in said test sample.

[0151] Exemplary embodiment 24 is the system of any preceding or following exemplary embodiment, wherein the progesterone metabolite of interest is progesterone sulfate.

[0152] Exemplary embodiment 25 is the system of any preceding or following exemplary embodiment, wherein the progesterone sulfate comprises at least one of 5β-pregnane-3α,20α-diol (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S); 5α-pregnane-3β-ol-20-one sulfate (PM5S); 5α-pregnane-3α,20α-diol disulfate (PM2DiS); or 5β-pregnane-3α,20α-diol disulfate (PM3DiS).

[0153] Exemplary embodiment 26 is a system of any preceding or following exemplary embodiment where PM3S is measured individually (PM3S), PM4S and PM5S are measured simultaneously, and PM2DiS and PM3DiS are measured simultaneously.

[0154] Exemplary embodiment 27 is the system of any preceding or following exemplary embodiment, where the mass spectrometry is tandem mass spectrometry.

[0155] Exemplary embodiment 28 is the system of any preceding or following exemplary embodiment, where the tandem mass spectrometry is a triple quadrupole tandem mass spectrometry.

[0156] Exemplary embodiment 29 is a system of any preceding or following exemplary embodiment, where selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) with ion summation, as appropriate, is used to select precursor ions and / or product ions.

[0157] Exemplary embodiment 30 is a system of any preceding or following exemplary embodiment, where PM3S is measured by MRM using the analyte peak for the transition 399.400→97.100.

[0158] Exemplary embodiment 31 is a system of any preceding or following exemplary embodiment, in which PM4S and PM5S are measured separately or together by MRM using an analyte peak for the transition 397.3→97.0 for PM5S and an analyte peak for the transition 397.2→97.0 for PM4S.

[0159] Exemplary embodiment 32 is a system of any preceding or following exemplary embodiment, where PM2DiS and / or PM3DiS are measured by MRM with ion summation.

[0160] Exemplary embodiment 33 is a system of any preceding or following exemplary embodiment, where the sum of the transitions 479.098→381.2+479.099→381.2+479.100→381.2+479.101→381.2+479.102→381.2 is used for detection of PM2DiS.

[0161] Exemplary embodiment 34 is a system of any preceding or following exemplary embodiment, where the sum of the transitions 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.1 may be used for detection of PM3DiS.

[0162] Exemplary embodiment 35 is a system of any preceding or following exemplary embodiment, further including a station and / or component for partially purifying a progesterone metabolite of interest from other components in a sample.

[0163] Exemplary embodiment 36 is a system of any preceding or following exemplary embodiment, further including a station and / or component for chromatographically separating the progesterone metabolite of interest from other components in the sample.

[0164] Exemplary embodiment 37 is the system of any preceding or following exemplary embodiment, where the sample is plasma or serum.

[0165] Exemplary embodiment 38 is a system of any preceding or following exemplary embodiment, wherein at least one stable isotope is added as an internal standard, and optionally the stable isotope-labeled internal standard comprises at least one of PM3S-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] sulfate); PM5S-d4 (i.e., 5α-pregnane-3β-ol-20-one-[2,2,4,4-d4] sulfate); PM2DiS-d4 (i.e., 5α-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate); and / or PM3DiS-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate).

[0166] Exemplary embodiment 39 is a system of any preceding or following exemplary embodiment, where at least one of the stations and / or components is controlled by a computer and / or a computer program product tangibly embodied in a non-transitory machine-readable storage medium.

[0167] Exemplary embodiment 40 is a computer program product tangibly embodied in a non-transitory machine-readable storage medium that includes instructions configured to perform any of the method steps of exemplary embodiments 1-22 or control any of the stations and / or components of exemplary embodiments 23-39.

[0168] Exemplary embodiment 41 is a computer program product of any preceding or following exemplary embodiment comprising instructions which, when executed on one or more data processors, cause said one or more data processors to perform operations to direct at least one of the following steps: providing a sample suspected of containing at least one progesterone metabolite; optionally chromatographically separating said at least one progesterone metabolite in the sample from other components; generating one or more precursor ions and one or more fragment ions specific for progesterone metabolites using tandem mass spectrometry; and determining the presence or amount of progesterone metabolites in said sample.

[0169] Exemplary embodiment 42 is a computer program product of any preceding or following exemplary embodiment comprising instructions that, when executed on one or more data processors, cause said one or more data processors to perform operations to direct at least one of: (a) generating one or more precursor ions from progesterone metabolites; (b) generating one or more product ions from said one or more precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating said detected ions with the presence or amount of metabolites of progesterone in said sample.

[0170] Exemplary embodiment 43 is a computer program product of any preceding or following exemplary embodiment, comprising instructions that, when executed on one or more data processors, cause said one or more data processors to perform operations to operate the system or any stations and / or components of the system to determine the presence or amount of a progesterone metabolite in a test sample, said system comprising: a station and / or component for providing a test sample suspected of containing a progesterone metabolite of interest; a mass spectrometry station and / or component for generating one or more precursor ions, generating one or more product ions from said one or more precursor ions, and fragmenting said progesterone metabolite of interest to determine the amount of the one or more precursor ions or the one or more product ions; and a station and / or component for determining the presence or amount of a progesterone metabolite in said test sample.

[0171] Exemplary embodiment 44 is the computer program product of any preceding or following exemplary embodiment, where the progesterone metabolite is progesterone sulfate.

[0172] Exemplary embodiment 45 is the computer program product of any preceding or following exemplary embodiment, wherein the progesterone sulfate comprises at least one of 5β-pregnane-3α,20α-diol (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S); 5α-pregnane-3β-ol-20-one sulfate (PM5S); 5α-pregnane-3α,20α-diol disulfate (PM2DiS); or 5β-pregnane-3α,20α-diol disulfate (PM3DiS).

[0173] Exemplary embodiment 46 is a computer program product of any preceding or following exemplary embodiment, where PM3S is measured individually, PM4S and PM5S are measured simultaneously, and PM2DiS and PM3DiS are measured simultaneously.

[0174] Exemplary embodiment 47 is the computer program product of any preceding or following exemplary embodiment, where the mass spectrometry is tandem mass spectrometry.

[0175] Exemplary embodiment 48 is the computer program product of any preceding or following exemplary embodiment, where the tandem mass spectrometry is triple quadrupole tandem mass spectrometry.

[0176] Exemplary embodiment 49 is a computer program product of any preceding or following exemplary embodiment, where precursor ions and / or product ions are selected using selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) optionally with ion summation.

[0177] Exemplary embodiment 50 is a computer program product of any preceding or following exemplary embodiment, where PM3S is measured by MRM using the analyte peak for the transition 399.400→97.100.

[0178] Exemplary embodiment 51 is a computer program product of any preceding or following exemplary embodiment, wherein PM4S and PM5S are measured separately or together by MRM using an analyte peak for the transition 397.3→97.0 for PM5S and an analyte peak for the transition 397.2→97.0 for PM4S.

[0179] Exemplary embodiment 52 is a computer program product of any preceding or following exemplary embodiment, where PM2DiS and / or PM3DiS are measured by MRM with ion summation.

[0180] Exemplary embodiment 53 is the computer program product of any preceding or following exemplary embodiment, where a sum of the transitions 479.098→381.2+479.099→381.2+479.100→381.2+479.101→381.2+479.102→381.2 is used for detection of PM2DiS.

[0181] Exemplary embodiment 54 is a computer program product of any preceding or following exemplary embodiment, where the sum of the transitions 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.1 may be used for detection of PM3DiS.

[0182] Exemplary embodiment 55 is the computer program product of any preceding or following exemplary embodiment, wherein the sample is subjected to a purification step prior to the initial fragmentation step (a).

[0183] Exemplary embodiment 56 is the computer program product of any preceding or following exemplary embodiment, where the purification step comprises chromatography.

[0184] Exemplary embodiment 57 is the computer program product of any preceding or following exemplary embodiment, where chromatography comprises high performance liquid chromatography (HPLC) or high throughput liquid chromatography (HTLC).

[0185] Exemplary embodiment 58 is the computer program product of any preceding or following exemplary embodiment, further comprising at least one of dilution and / or protein precipitation of the sample prior to chromatography.

[0186] Exemplary embodiment 59 is the computer program product of any preceding or following exemplary embodiment, further comprising the addition of a stable isotope labeled internal standard.

[0187] Exemplary embodiment 60 is the computer program product of any preceding or following exemplary embodiment, wherein the stable isotope labeled internal standard comprises at least one of PM3S-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] sulfate); PM5S-d4 (i.e., 5α-pregnane-3β-ol-20-one-[2,2,4,4-d4] sulfate); PM2DiS-d4 (i.e., 5α-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate); and / or PM3DiS-d4 (i.e., 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate).

[0188] Exemplary embodiment 61 is the computer program product of any preceding or following exemplary embodiment, wherein the sample is serum or plasma.

[0189] Exemplary embodiment 62 is the computer program product of any preceding or following exemplary embodiment, wherein the LLOQ for progesterone sulfate is 1 ng per 100 μL of sample.

[0190] Exemplary embodiment 63 is the computer program product of any preceding or following exemplary embodiment, wherein the ULOQ of progesterone sulfate is 500 ng per 100 μL of sample.

[0191] Exemplary embodiment 64 is the computer program product of any preceding or following exemplary embodiment, wherein the amount of progesterone sulfate is used to distinguish whether cutaneous pruritus of pregnancy is an early sign of (ICP) or is due to benign pruritus of pregnancy in a subject.

[0192] Various embodiments of the present disclosure are described herein. It should be recognized that these embodiments are merely illustrative of the present disclosure. After reading the foregoing description, variations of the preferred embodiments may become apparent to those skilled in the art. It is anticipated that such variations may be utilized by those skilled in the art as appropriate, and that the present disclosure is intended to be practiced differently from the specific description herein. Accordingly, the present disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the present disclosure unless otherwise indicated or clearly contradicted by context.

Claims

1. 1. A method for determining the presence or amount of a progesterone metabolite in a sample from a subject by mass spectrometry, comprising: (a) generating one or more precursor ions from the progesterone metabolite; (b) generating one or more product ions of the one or more precursor ions; (c) detecting the presence or amount of the one or more precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating the detected ions with the presence or amount of a progesterone metabolite in the sample.

2. 2. The method of claim 1, wherein the progesterone metabolite is progesterone sulfate.

3. 3. The method of any one of claims 1-2, wherein the progesterone sulfate comprises at least one of 5β-pregnane-3α,20α-diol sulfate (PM3S); 5α-pregnane-3α-ol-20-one sulfate (PM4S); 5α-pregnane-3β-ol-20-one sulfate (PM5S); 5α-pregnane-3α,20α-diol disulfate (PM2DiS); or 5β-pregnane-3α,20α-diol disulfate (PM3DiS).

4. The method according to any one of claims 1 to 3, wherein the mass spectrometry is multiple reaction monitoring tandem mass spectrometry.

5. PM3S is measured using the transition 399.400→97.100; PM5S is measured using the transition 397.3→97.0; PM4S is measured using the transition 397.2→97.0; PM2DiS is measured using the transition 479.098→381.2+479.099→381.2+479.100→381.2+479.101→3 5. The method according to claim 1, wherein PM3DiS is measured using the sum of the transitions 479.098→399.1+479.099→399.1+479.100→399.1+479.101→399.1+479.102→399.

1.

6. The method of any one of claims 1 to 5, wherein the sample is subjected to a purification step prior to mass spectrometry.

7. The method of claim 6 , wherein the purification step comprises high performance liquid chromatography (HPLC).

8. The method according to any one of claims 6 to 7, wherein the purification step comprises at least one of dilution and / or protein precipitation of the sample.

9. 9. The method according to claim 1, wherein PM3S is measured individually, PM4S and PM5S are measured simultaneously, and PM2DiS and PM3DiS are measured simultaneously.

10. The method of any one of claims 1 to 9, further comprising the addition of an internal standard labeled with a stable isotope.

11. The stable isotope-labeled internal standard was 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] sulfate (PM3S-d 4 ), 5α-pregnane-3β-ol-20-one-[2,2,4,4-d4] sulfate (PM5S-d 4 ), 5α-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate (PM2DiS-d 4 ), or 5β-pregnane-3α,20α-diol-[2,2,4,4-d4] disulfate (PM3DiS-d 4 11. The method of claim 10, comprising at least one of:

12. The method according to any one of claims 1 to 11, wherein the sample is human serum or plasma.

13. The method according to any one of claims 2 to 12, wherein the lower limit of quantification (LLOQ) of the progesterone sulfate is 1 ng per 100 μL of sample.

14. The method of any one of claims 2 to 13, wherein the upper limit of quantification (ULOQ) of the progesterone sulfate is 500 ng per 100 μL sample.

15. The method according to any one of claims 2 to 14, wherein the amount of progesterone sulfate is used to distinguish whether cutaneous pruritus of pregnancy is an early sign of (ICP) or is due to benign pruritus of pregnancy in a subject.

16. 1. A system for determining the presence or amount of a progesterone metabolite in a test sample from a subject, the system comprising: stations and / or components for providing a test sample suspected of containing a progesterone metabolite of interest; a station and / or component for mass spectrometry to fragment a progesterone metabolite of interest to produce one or more precursor ions and one or more product ions; and a station and / or component for determining the presence or amount of a progesterone metabolite of interest in said sample. Including, the system.

17. 17. The system of claim 16, wherein the target progesterone metabolite is progesterone sulfate.

18. The system of any one of claims 16 to 17, further comprising a station and / or component for partially purifying the progesterone metabolite of interest in the sample from other components.

19. The system of any one of claims 16 to 18, further comprising a station and / or component for chromatographically separating the progesterone metabolite of interest from other components in the sample.

20. 1. A computer program product which, when executed on one or more data processors, causes the one or more data processors to perform operations that direct at least one of the following steps: (a) generating one or more precursor ions from progesterone metabolites; (b) generating one or more product ions of the one or more precursor ions; (c) detecting the presence or amount of one or more of the precursor ions generated in step (a) or one or more product ions of step (b), or both; and correlating the detected ions with the presence or amount of metabolites of progesterone in the sample.